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Colorectal cancer (CRC) screening has come of age in Canada, with every province now having a screening program either implemented 
or well underway. These programs are based on the detection of fecal 
occult blood, with positive results triggering colonoscopy for definitive 
diagnosis. This approach is supported by high-level evidence demonstrat-
ing a mortality benefit for individuals screened in this manner (1-3).
Fecal occult blood testing (FOBT) uses indirect methods to test for 
the presence of hemoglobin, which can be affected by chemicals, such as 
vitamin C, or heme from other sources such as red meat. In contrast, 
fecal immunochemical tests (FIT) use an antibody to detect human glo-
bin directly (4). These assays may offer advantages of greater specificity 
and sensitivity, and improved adherence. Most FITs produce a visual 
colour change on a strip to indicate a positive result, but some are ana-
lyzed using automated systems in a laboratory to provide a quantitative 
result. 
In the current issue of the Canadian Journal of Gastroenterology, 
Rabeneck et al (5) (pages 131-147) report on the findings of the FIT 
Guidelines Expert Panel, a group convened to evaluate the latest evi-
dence on the use of FITs and to advise ‘ColonCancerCheck,’ the Ontario 
CRC screening program (5). The group was specifically interested in FIT 
performance characteristics, usability factors and specimen stability.
Following a comprehensive search of the published literature between 
1996 and June 2010, two systematic reviews, three randomized con-
trolled trials and four other studies were reviewed in detail. The panel 
prepared a review of the 13 different FITs currently approved for use in 
Canada and reviewed websites of pertinent provincial and national 
health care organizations for relevant evidence. 
Three studies compared FIT performance with standard guaiac FOBT 
(gFOBT). CRC detection was the primary outcome, but some studies 
also assessed advanced adenoma (AA) detection. Overall, FIT had 
higher positivity rates (4.8% to 11.2%) than standard gFOBT (2.4% to 
7.9%), with similar or slightly lower specificity for CRC detection 
(90.1% to 95.8% versus 92.4% to 98.1%), resulting in a higher rate of 
detection of CRC and AA (1.4% FIT versus 0.6% gFOBT). Sensitivity 
was assessed in only one study, but was significantly higher for FIT for 
both CRC detection (92.3% versus 30.8% [P<0.01]) and AA detection 
(33.9% versus 13.6% [P<0.05]). One study compared FIT with Hemoccult 
SENSA (Beckman Coulter, USA), a more sensitive gFOBT. In that 
study, FIT positivity was significantly lower than Hemoccult SENSA 
(3.2% versus 10.1% [P<0.01]), but with significantly higher specificity 
for CRC (96.9% versus 90.1% [P<0.01]) and AA detection (97.3% ver-
sus 90.6% [P<0.01]). The positive predictive value (PPV) for detection 
of both CRC (5.2% versus 1.5% [P<0.01]) and AA (19.1% versus 8.9% 
[P<0.01]) was superior for FIT compared with Hemoccult SENSA.
Studies that evaluated different cut-off levels to define a positive FIT 
demonstrated increased PPV and specificity at higher cut-off levels 
(>100 ng/mL) at the expense of a decrease in positivity rate and 
sensitivity.
All three studies that evaluated patient participation rates noted sig-
nificant differences in favour of FIT, with rates ranging from 59.6% to 
68%, compared with rates of 46.9% to 55% for FOBT.
The authors were interested in assessing the temperature stability of 
FITs that used a vial collection method. One study that examined this 
reported lower positivity rates in warmer months (OR 0.83 [95% CI 
0.73 to 0.90] summer compared with winter) and a reduced chance of a 
positive test for every increase of 1°C average ambient air temperature 
in the five to 11 days preceding test analysis (OR 0.993 [95% CI 0.989 
to 0.996]). A recent Dutch study (6) made the same observations. 
However, in that study, return times of up to 10 days did not affect FIT 
performance, suggesting good specimen stability with respect to time to 
processing (6).
The findings of this expert panel suggest that FIT is superior to 
gFOBT for CRC screening. It has higher sensitivity, PPV and CRC 
detection rates compared with standard gFOBT, and greater specificity 
and PPV compared with the most sensitive gFOBT, Hemoccult SENSA. 
An additional advantage of FIT is superior performance in detecting 
AAs, enabling not just early detection of CRC but also true prevention 
by identifying advanced lesions that can be managed endoscopically. 
Perhaps of greatest importance, FIT is more acceptable to patients than 
gFOBT, with participation rates approximately 10% greater than for 
other FOBTs. This is likely related to a simpler specimen collection pro-
cess, no requirement for dietary restrictions and, for most FITs, collection 
of just one specimen. Indeed, in northern California (USA), a significant 
improvement in CRC screening participation has been associated with 
the use of FIT in a comprehensive program, with participation rates ris-
ing from 35% in 2004 to 75% in 2011 (4). 
Most FIT manufacturers recommend using a cut-off level of 100 ng/mL 
to define a positive test. However, adjusting that level downward alters 
the performance characteristics toward greater sensitivity and test posi-
tivity at the expense of less specificity and a lower PPV. There are 
resource implications associated with more positive screening tests (ie, 
more colonoscopies generated), but ultimately, this leads to more CRC 
detection. A Dutch cost-effectiveness analysis concluded that 50 ng/mL 
was the preferred cut-off level in their screening program (7). It is not 
known whether that result would apply to screening programs operating 
within Canada. 
In conclusion, the FIT Guidelines Expert Panel has completed a 
comprehensive review of FIT for CRC screening. Their findings are con-
sistent with those of other societies and provide a solid evidentiary base 
to implement FIT for CRC screening in Canada. Attention should be 
devoted to the temperature stability of FIT kits, a very relevant issue for 
the extreme seasonal temperature variations in Ontario and other parts 
of Canada. Further investigation should be conducted to allow for the 
identification of the optimal cut-off point to define a positive test.  
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